BioSpace News Archive

Oculis Holding AG announced it has won the 2023 Knowledge Award from the Icelandic Association of Business and Economics.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced an agreement with The University of Texas MD Anderson Cancer Center to support research focused on metastatic renal cell carcinoma treatment selection and response.

Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, reported that the United States Patent and Trademark Office has issued a Notice of Allowance for its patent application covering the Company’s dual mechanism SERCA2a Activators.

Salarius Pharmaceuticals, Inc. announces the presentation of a poster related to the company’s novel molecular glue, SP-3164, at the European Hematology Association 2023 Hybrid Conference, which was held in Frankfurt, Germany and virtually June 8-11, 2023.

Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, announced that the Company will be taking part in the following conferences in June.

Daxor Corporation, the global leader in blood volume measurement technology, announced that Michael Feldschuh, CEO and President has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.

Bionano Genomics, Inc. announced the 2023 winners of its Innovator Research Grant program, including grand prize winner Dr. Michael Khodadoust at Stanford University.

Adverum Biotechnologies, Inc. announces an agreement granting Ray Therapeutics a non-exclusive, royalty bearing license of Adverum’s proprietary AAV.7m8 intravitreal vector capsid to be used in conjunction with Ray’s optogenetics payload.

Day One Biopharmaceuticals, Inc. announced the closing on June 12, 2023 of its previously announced underwritten public offering of 13,269,231 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,730,769 additional shares, at a public offering price of $13.00 per share.

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the filling of its vacant board seat with the appointment of Bridget Martell, M.A., M.D. to its Board of Directors.